Table 1.
Clinico-demographic characteristics of the study cohort
| Characteristics | HC | HHC/IGRA+ve | HHC/IGRA-ve | p value |
|---|---|---|---|---|
| Number | 25 | 26 | 25 | |
|
| ||||
| Age, years, median (IQR) | 36 (29 – 47) | 39.5 (28 – 54.8) | 40 (33 – 47) | 0.492 |
|
| ||||
| Gender, male, n (%) | 14 (56%) | 9 (34.6%) | 7 (28%) | 0.044* |
|
| ||||
| BMI, median (IQR) | 25.4 (22.9 – 28.4) | 25.8 (23 – 30.23) | 24.7 (21.9 – 28.4) | 0.748 |
|
| ||||
| BCG vaccination, n (%) | 21 (84%) | 21 (80.8%) | 20 (80%) | 0.379 |
|
| ||||
| Residential area, urban, n (%) | 13 (52%) | 13 (50%) | 13 (52%) | 0.986 |
|
| ||||
| Bilirubin, (mg/dl), median (IQR) | 0.7 (0.6 – 0.85) | 0.7 (0.6 – 0.83) | 0.6 (0.45 – 0.9) | 0.493 |
|
| ||||
| SGOT, (U/L), median (IQR) | 25 (16 – 32) | 21.5 (18 – 26.5) | 20 (17 – 25.5) | 0.078† |
|
| ||||
| SGPT, (U/L), median (IQR) | 25 (16 – 43.5) | 19.5 (16 – 26) | 19 (14 – 22.5) | 0.075† |
|
| ||||
| ALP, (U/L), median (IQR) | 69 (51 – 74) | 69 (54.8 – 90.3) | 58 (49 – 73) | 0.109 |
|
| ||||
| Creatinine, (mg/dl), median (IQR) | 0.8 (0.8 – 1.0) | 0.8 (0.7 – 0.9) | 0.8 (0.7 – 0.9) | 0.152 |
|
| ||||
| Urea, (mg/dl), median (IQR) | 23 (20 – 34) | 22.5 (16.7 – 25.8) | 20 (17 – 23.5) | 0.052† |
|
| ||||
| Neutrophil count (10×3/µL), median (IQR) | 4.57 (4.07 – 5.31) | 4.4 (3.4 – 6.5) | 4.2 (3.7 – 5.53) | 0.693 |
| %, median (IQR) | 59.7 (52 – 63.5) | 60.6 (43.4 – 66.3) | 55.1 (50.5 – 62.9) | 0.954 |
|
| ||||
| Lymphocyte count (10×3/µL), median (IQR) | 2.44 (2.07 – 2.81) | 2.62 (2.07 – 3.32) | 2.2 (1.8 – 2.86) | 0.263 |
| %, median (IQR) | 29.6 (27.3 – 53.6) | 31.2 (25.1 – 39.6) | 31.1 (24.6 – 35.9) | 0.925 |
|
| ||||
| Monocyte count (10×3/µL), median (IQR) | 0.52 (0.43 – 0.65) | 0.57 (0.43 – 0.64) | 0.51 (0.41 – 0.7) | 0.974 |
| %, median (IQR) | 6.6 (5.6 – 7.8) | 6.85 (5.15 – 7.65) | 6.6 (5.8 – 9.1) | 0.828 |
|
| ||||
| Eosinophil count (10×3/µL), median (IQR) | 0.19 (0.11 – 0.27) | 0.25 (0.18 – 0.48) | 0.2 (0.4 – 0.39) | 0.166 |
| %, median (IQR) | 2.3 (1.35 – 4.25) | 3.55 (1.93 – 6.7) | 2.9 (1.65 – 5.05) | 0.189 |
|
| ||||
| Basophil count (10×3/µL), median (IQR) | 0.04 (0.03 – 0.06) | 0.05 (0.04 – 0.06) | 0.04 (0.03 – 0.06) | 0.384 |
| %, median (IQR) | 0.6 (0.45 – 0.8) | 0.6 (0.5 – 0.9) | 0.6 (0.5 – 0.75) | 0.719 |
|
| ||||
| Medical conditions, n (%) | ||||
| Sickness past 14-days | 6 (24%) | 4 (15.4%) | 4 (16%) | 0.479 |
| Diabetes | 5 (20%) | 8 (30.8%) | 6 (24%) | 0.753 |
| Hypertension | 6 (24%) | 4 (15.4%) | 4 (16%) | 0.479 |
| COPD/asthma | 2 (8%) | 2 (7.7%) | 3 (12%) | 0.632 |
| Dialysis | 2 (8%) | 0 (0%) | 2 (8%) | 1.000 |
| History of COVID-19 | 6 (24%) | 4 (15.4%) | 4 (16%) | 0.450 |
| Smoking | 2 (8%) | 1 (3.85%) | 0 (0%) | 0.153 |
| Alcohol | 4 (16%) | 2 (7.7%) | 0 (0%) | 0.141 |
All categorical variable reported as numbers (n) and percentages (%), and continuous variables reported as median, IQR. HC, healthy control; HHC, household contact, IGRA, interferon gamma release assay; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic-pyruvic transaminase; ALP, alkaline phosphatase. All continuous variables were compared using the Kruskal-Wallis test, whilst all the categorical variables were compared using Chi-Square test.
*
Represent p<0.05,
†
having a trend of significance.